Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
27 déc. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for...
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
20 nov. 2023 07h30 HE
|
Zevra Therapeutics
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
07 nov. 2023 07h00 HE
|
Zevra Therapeutics
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results.
Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET
31 oct. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
19 oct. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global...
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
10 oct. 2023 07h30 HE
|
Zevra Therapeutics
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting
05 oct. 2023 07h30 HE
|
Zevra Therapeutics
Presentation to focus on the arimoclomol program for the treatment of Niemann-Pick Disease type C and related early access programs CELEBRATION, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Zevra...
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
02 oct. 2023 07h30 HE
|
Zevra Therapeutics
Data generated to date indicate SDX is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future Phase 3 trial Topline data from completed trial expected in...
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
20 sept. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
09 sept. 2023 20h00 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation...